Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.

Article  PubMed  Google Scholar 

Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389:10085.

Kankanala VL, Mukkamalla SKR. Carcinoembryonic antigen. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: http://www.ncbi.nlm.nih.gov/books/NBK578172/

Scarà S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. In: Scatena R, editor. Advances in cancer biomarkers. Dordrecht: Springer; 2015. pp. 247–60. (Advances in Experimental Medicine and Biology; vol. 867). Available from: https://link.springer.com/https://doi.org/10.1007/978-94-017-7215-0_15

Yu H, Li R, Zhang L, Chen H, Bao Y, Jia W. Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients. Exp Diabetes Res. 2012;2012:1–5.

Article  Google Scholar 

Gul K, Nas S, Ozdemir D, Ersoy R, Cakir B, Gumus M. CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications. Am J Med Sci. 2011;341(1):28–32.

Article  PubMed  Google Scholar 

Kim SH, Baek C, Lee ok, Park KA, Baek TS, Jin HS. Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes. Endocrine. 2014;46(2):249–55.

Article  CAS  PubMed  Google Scholar 

Esteghamati A, Hafezi-nejad N, Zandieh A, Sheikhbahaei S, Emamzadeh-Fard S, Nakhjavani M. CA 19-9 is associated with poor glycemic control in diabetic patients: role of insulin resistance. Clin Lab. 2014;60(03):441–7.

Cui L, Lv N, Li B, Tao J, Zheng X, Yan Y, et al. Serum CA 19–9 level is correlated to the clinical characteristics and chronic complications of patients newly diagnosed with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2021;129(08):581–6.

Article  CAS  PubMed  Google Scholar 

Benhamou PY, Vuillez JP, Halimi S, Meffre G, Bachelot I. Influence of metabolic disturbances of diabetes mellitus on serum CA 19-9 tumor marker. Diabete Metab. 1991;17(1):39–43.

CAS  PubMed  Google Scholar 

Huang Y, Xu Y, Bi Y, Xu M, Lu J, Wang T, et al. Relationship between CA 19-9 levels and glucose regulation in a middle‐aged and elderly Chinese population. J Diabetes. 2012;4(2):147–52.

Article  CAS  PubMed  Google Scholar 

Tu Y, Yu H, Zhang P, Di J, Han X, Wu S, et al. Decreased serum CA19-9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux-en-Y gastric bypass. J Diabetes Investig. 2014;5(6):694–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murai J, Soga S, Saito H, Otsuki M, Kitada T, Saisho Y, et al. Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. Endocr J. 2013;60(7):885–91.

Article  CAS  PubMed  Google Scholar 

Yan P, Li J, Zhang Y, Dan X, Wu X, Zhang X, et al. Association of circulating carbohydrate antigen 19-9 level with type 2 diabetic kidney disease in Chinese adults: a cross-sectional study. Diabetes Metab Syndr Obes. 2024;17:467–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng YC, Li YH, Hsu CY, Lee IT. Synergistic association of carcinoembryonic antigen and carbohydrate antigen 19-9 on the risk of abnormal glucose regulation. DMSO. 2020;13:1933–42.

Article  CAS  Google Scholar 

Ata N, Dal K, Kucukazman M, Yeniova AÖ, Karakaya S, Unsal O et al. The effect of glycemic control on CEA, CA 19-9, amylase and lipase levels. Open Med. 2014;10(1):8. https://doi.org/10.1515/med-2015-0002/html

Zhang D. Correlation between blood glucose control and levels of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with type-2 diabetes mellitus. DMSO. 2022;15:2489–95.

Article  CAS  Google Scholar 

Cai R, Kong Q, Wang Z, Gao Z, Huo Y. Correlation between tumor markers and type 2 diabetes mellitus complications and their related influencing factors. Ann Palliat Med. 2022;11(1):58–67.

Article  PubMed  Google Scholar 

Shang X, Song C, Du X, Shao H, Xu D, Wang X. The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control. SMJ. 2017;38(2):204–8.

Article  Google Scholar 

Zayed AA, Beano AM, Amer FN, Maslamani JM, Zmaili MA, Al-Khudary TH, et al. Serum levels of carcinoembryonic antigen in patients with type 2 diabetes. Endocr Pract. 2016;22(11):1310–8.

Article  PubMed  Google Scholar 

Hasan M, Mohieldein A. Association between serum carcinoembryonic antigen level and oxidative stress parameters among diabetic females. Int J Clin Exp Med. 2015;8(4):6489–94.

PubMed  PubMed Central  Google Scholar 

Lu J, Wang H, Zhang X, Yu X. HbA1c is positively associated with serum carcinoembryonic antigen (CEA) in patients with diabetes: a cross-sectional study. Diabetes Ther. 2018;9(1):209–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19–40.

Article  CAS  PubMed  Google Scholar 

Diagnosis and management of type 2 diabetes (HEARTS-D). Geneva:World Health Organization; 2020 (WHO/UCN/NCD/20.1). Licence: CC BY-NC-SA 3.0 IGO.

Lo CKL, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14(1):45.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; 2023. Available from www.training.cochrane.org/handbook

Duan X, Wang W, Pan Q, Guo L. Type 2 diabetes mellitus intersects with pancreatic cancer diagnosis and development. Front Oncol. 2021;11:730038.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman R, Harris Z, Ernst B, Mussallem D, Larsen A, Gowin K. Lifestyle factors and cancer: a narrative review. Mayo Clin Proc Innov Qual Outcomes. 2024;8(2):166–83.

Article  PubMed  PubMed Central  Google Scholar 

Schmeer KK, Tarrence J. Racial-ethnic disparities in inflammation: Evidence of weathering in childhood? J Health Soc Behav. 2018;59(3):411–28.

Article  PubMed  PubMed Central  Google Scholar 

Petit JM, Vaillant G, Olsson NO, Guignier F, Collignon S, Verges B, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group. Gastroenterol Clin Biol. 1994;18(1):17–20.

CAS  PubMed  Google Scholar 

Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgrad Med. 2020;132(8):676–86.

Article  CAS  PubMed  Google Scholar